Heron Therapeutics is trading 5.3% up at $0.54 amid a broad risk-on rally in U.S. equities and strength in biotech stocks.
- The move appears driven by positive overall market sentiment and sector-wide tailwinds rather than a company-specific catalyst.
- There are no fresh headlines, earnings reports, FDA decisions, or analyst calls tied to the stock for August 4, 2026.